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Abstract: Recombinant Adenoviral vectors represent one of the best gene transfer platforms 
due to their ability to efficiently transduce a wide range of quiescent and proliferating cell 
types  from  various  tissues  and  species.  The  activation  of  an  adaptive  immune  response 
against the transduced cells is one of the major drawbacks of first generation Adenovirus 
vectors and has been overcome by the latest generation of recombinant Adenovirus, the 
Helper-Dependent Adenoviral (HDAd) vectors. HDAds have innovative features including 
the  complete  absence  of  viral  coding  sequences  and  the  ability  to  mediate  high  level 
transgene expression with negligible chronic toxicity. This review summarizes the many 
aspects  of  HDAd  biology  and  structure  with  a  major  focus  on  in  vivo  gene  therapy 
application and with an emphasis on the unsolved issues that these vectors still presents 
toward clinical application. 
Keywords: Helper Dependent Adenovirus; liver transduction; lung transduction; innate and 
adaptive immune response 
 
1. Introduction 
Adenovirus (Ad)-derived gene therapy vectors have been the focus of considerable interest for their 
potential application as a delivery vehicle for human gene therapy. Even though these vectors were 
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initially  conceived  for  the  treatment  of  genetic  disorders,  so  far  the  majority  of  their  clinical 
application has been for cancer treatment. Some of the most important aspects of Ad-derived vectors 
that have gained the attention of the gene therapy community include: 1) the ability to infect with high 
efficiency a variety of both quiescent and proliferating cell types, 2) Ad vectors can be easily grown to 
very high titer, allowing the experimenter to transduce a large number of cells and/or tissue target of 
large animals, and 3) the absence of vector genome integration thereby reduces the likelihood for 
germ-line transmission and insertional mutagenesis, which represents an important safety feature [1] 
for human clinical applications. First generation adenoviral (FGAd) vectors are rendered replication-
deficient by the deletion of the viral early region (E1). However, leaky expression of viral genes from 
the vector backbone is still present, leading to loss of transgene expression due to an adaptive cellular 
immune  response  against  the  transduced  cells  and  chronic  toxicity.  Further  deletion  in  the  vector 
backbone (E2, E4) still allows for the low level expression of viral genes and does not preclude an 
immune reaction towards transduced tissues [2,3]. In contrast, helper-dependent adenoviral (HDAd) 
vectors  are  devoid  of  all  viral  coding  sequences,  and  have  shown  tremendous  potential  for  the 
treatment of genetic disease, allowing for persistent transgene expression for years in the apparent 
absence of any type of adaptive immune response and chronic toxicity [4]. HDAds can mediate high 
efficiency transduction, do not integrate in the host genome, and have a large cloning capacity of up to 
37 kb, which allows for the delivery of multiple trangenes or entire genomic loci, or large cis-acting 
elements to enhance or regulate tissue-specific transgene expression (for example, inclusion of the 
large control elements of the human cytokeratin 18 gene for specific expression in the epithelium [5] 
or  inclusion  of  the  human  apolipoprotein  E  Hepatic  Control  Region  for  enhanced  liver  specific 
expression [6]). This review will focus on the general features of the HDAd vectors and the most 
recent advance in the clinical application of these vectors. 
2. Adenoviruses 
Adenoviruses (Ad) are non-enveloped double stranded DNA viruses of 60-110 nm in diameter. 
During natural infection, the main target is epithelial cells of the respiratory and gastrointestinal tract. 
Ad can cause relatively mild, self-limiting diseases of the upper respiratory tract, gastroenteritis, or 
conjunctivitis  in  some  cases  but  most  infections  are  asymptomatic  in  immunocompetent  
individuals [7-11]. Importantly, adenoviruses have not been associated with any neoplastic disease in 
humans [7]. Amongst the ~50 serotypes of human Ad, the most extensively characterized are serotypes 
2 (Ad2) and 5 (Ad5) belonging to subgroup C. The 36 kb genome of Ad 2 and Ad5 is flanked by  
cis-acting inverted terminal repeats (ITRs), which are required for viral DNA replication in cis. A  
cis-acting packaging signal (Ψ), required for the encapsidation of the Ad genome, is located near the 
left ITR (relative to the conventional map of Ad) (Figure 1). The Ad genome comprises two set of 
genes (Figure 1): the early region genes, E1A, E1B, E2, E3, and E4, are transcribed before DNA 
replication and the late region genes, L1 to L5, are transcribed and expressed at high levels after the 
initiation of DNA replication. The E1A transcription unit encodes two major E1A proteins that are 
involved in transcriptional regulation of the virus and stimulation of the host cell to enter an S phase-
like state. The two major E1B proteins are involved in stimulation of viral mRNA transport, blocking 
E1A-induced apoptosis and blocking host mRNA transport. The E2 region can be divided into two Viruses 2010, 2                         
 
 
1888 
sub-regions: E2a encodes the DNA-binding protein and E2b encodes the viral polymerase and terminal 
protein  precursor.  The  E3  region  encodes  at  least  seven  proteins,  most  of  which  have 
immunomodulatory functions and are specifically involved in host immune evasion. The E4 region 
encodes at least six proteins involved in DNA replication, enhancement of the late gene expression, 
and decrease host protein synthesis. Alternative splicing of a single transcript, referred to as late region 
genes, gives rise to all the mRNA encoding virion structural proteins. The expression of late region 
genes is regulated by a common major late promoter (MLP). 
Figure 1. Transcription map of human adenovirus serotype 5. The 100 map unit (~36 kb) 
genome is divided into four early region transcription units, E1–E4, and five families of 
late  mRNA,  L1–L5,  which  are  alternative  splice  products  of  a  common  late  transcript 
expressed  from  the  major  late  promoter  (MLP)  located  at  16  map  units.  Four  smaller 
transcripts, pIX, IVa, and VA RNA’s I and II, are also produced. The 103 bp inverted 
terminal repeats (ITRs) are located at the termini of the genome and are involved in viral 
DNA replication, and the packaging signal (ψ) located from nucleotides 190 to 380 at the 
left end is involved in packaging of the genome into virion capsids. Other late transcripts 
include the RNA polymerase III. 
 
 
Infection of the host cell is a two stage process involving an initial binding of the Ad fiber protein 
with CAR (coxsackie-adenovirus receptors) on the cell surface [9-12]. Then a secondary interaction 
occurs between the arginine-glycine-aspartic acid (RGD) motif present on the virion penton base and 
αvβ3 and αvβ5 integrins on the host cells, which in turn initiates receptor-mediated endocytosis via 
clathrin-coated pits [12-15].The efficiency of infection, which is dependent on Ad binding and entry, is 
directly related to the level of primary and secondary receptors on the cell surface [12,14]. After Ad 
internalization,  the  virion  escapes  from  the  early  endosome  into  the  cytosol  prior  to  lysosome 
formation [16,17]. During the translocation along the microtubule network toward the nucleus, the 
virion is disassembled and the DNA is released into the nucleus [18]. Once in the nucleus, viral DNA 
replication (beginning at 6-8 h postinfection) and assembly of progeny virion occur. The entire life 
cycle takes about 24-36 h and generates about 10
4 virions per infected cell. Viruses 2010, 2                         
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3. Early-generation Adenoviral vectors 
The basic notion that permitted the construction of first generation of Ad vectors (FGAd) is based 
on the fact that up to 10% of Ad viral DNA molecules become circularized following infection of 
mammalian cells [19]. Therefore, the entire Ad genome can be manipulated as an infectious bacterial 
plasmid by using standard molecular biology techniques. Indeed, the Ad genomic plasmid could be 
easily and stably propagated in E. coli and was capable of generating infectious viruses following 
transfection into permissive mammalian cells. The earliest version of FGAd vectors were prepared by 
substituting E1 region of Ad5 with a transgene. This type of vector can deliver transgenes up to 5 kb 
and  cannot  replicate  in  transduced  cells,  because  they  lack  the  E1  region  which  controls  the 
transactivation of genes involved in viral replication. An E1 deficient (ΔE1) vector must be propagated 
in a permissive cell line, engineered to provide the E1 functions in trans. While the deletion of E1 in 
FGAd results in a replication-defective vector, nonetheless E2, E3, and E4 promoters are still active 
and result in viral low level DNA replication and expression of viral genes, especially at high doses of 
infection [20,21]. This leaky expression of viral proteins precludes long-term transgene expression in 
vivo due to the strong cytotoxic immune reaction mounted against the transduced cells, resulting in the 
extinction of transgene expression within few weeks [22-24]. Therefore, in order to minimize the 
immune reaction toward the viral antigens, Ad vectors with further deletion of essential viral genes 
have been generated. Second generation or multiply-deleted Ad vectors carrying mutation or alteration 
in E2 or E4 regions in addition to E1 were constructed in parallel with the development of more 
complex  producer  cell  lines  capable  of  supporting  their  replication  by  trans-complementing  the 
additional  deletions  [20].  However,  viral  coding  sequences  still  remain  and  therefore  so  do  the 
potential for their expression and related toxicity. The advantages of multiply-deleted Ad vectors over 
FGAd remain controversial as some studies show them to be superior in terms of toxicity and duration 
of transgene expression [25,26] while some others do not [22,27-29].  
4. HDAd 
The  liver  toxicity  and  the  cellular  immune  response  triggered  by  early  generation  Ad  vectors 
constituted a great incentive for the construction of a new type of vector completely devoid of all 
adenoviral genes, referred to as Gutless Adenovirus or Helper-dependent Adenoviral (HDAd) vector. 
HDAds are constructed by removing all viral sequences from the vector genome except the packaging 
sequence and inverted terminal repeats, thereby eliminating the issue of residual viral gene expression 
associated with early generation Ad vectors. Currently, the most efficient method for generating HDAd 
is the Cre/loxP system; this method was the result of pioneering work by Frank Graham and co-
workers in 1996 [30]. In this system, the HDAd genome is constructed in a bacterial plasmid and 
contains the expression cassette of interest and ~500 bp of cis-acting Ad sequences necessary for 
vector DNA packaging (Ψ) and replication (ITRs). In order to obtain efficient packaging, the inclusion 
of stuffer DNA is required to maintain the size of the vector within appropriate limits. The size of 
HDAd vectors below ~27 kb undergo DNA rearrangement to increase the size of the genome to 27 to 
38 kb [31,32]. To convert or rescue the “plasmid form” of HDAd to the “viral form”, the plasmid is 
first digested with the appropriate restriction enzyme to liberate the HDAd genome from the bacterial Viruses 2010, 2                         
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plasmid sequences. Then, 293 cells expressing Cre are transfected with the linearized HDAd genome 
and subsequently infected with a helper virus. The helper virus is a FGAd bearing a packaging signal 
flanked by loxP sites in its genome and trans-complement the replication and encapsidation of the 
HDAd genome. Following the infection of 293 Cre cells, the packaging signal is excised from the 
helper virus genome by Cre-mediated site-specific recombination between the two loxP sites, and this 
precludes the packaging of the helper virus (Figure 2). Further improvements to this system have been 
made, which has permitted large scale manufacture of high quality HDAd with extremely low levels of 
helper  virus  contamination  [33]  for  large  animal  preclinical  studies  [34-39].  Indeed,  using  this 
improved system [33], cGMP grade HDAd has been manufactured to treat patients with anemia with 
very encouraging results [159]. In addition to the Cre/loxP system, the analogous FLP/frt systems have 
also been developed for the production of HDAds [40,41] although refinement of these systems have 
not progress as far. 
One of the most attractive features of HDAd vectors is the long term expression of the transgene, 
which will be discussed in detail below. In this regard, Jager et al. have recently shown that compared 
to plasmid non viral DNA, the HDAd genome, which exists predominantly as linear monomers in the 
nucleus of the cell, seems to be more stable [42,43]. Several potential mechanism that could explain 
the persistence of HDAd genome have been proposed by the authors: HDAd genomes 1) replicate 
episomally,  2)  possess  a  nuclear  retention  signal,  3)  circularize,  4)  integrate  or  6)  associate  with 
histones  [43].  Further  investigations  are  needed  to  fully  elucidate  this  phenomenon  to  permit  the 
manipulation of HDAd genome in order to render it even more stable and safe. Some other important 
considerations  concerning  HDAd  construction  and  production  are  the  vector  genome  size  for 
encapsidation  and  the  composition  of  the  stuffer D N A .  Vector  genome  size  below  27Kb  were 
inefficiently packaged and undergo DNA rearrangement to produce larger genome closer to the wild 
type  Ad5  genome  size  (approximately  30Kb)  [31].  Vector  genome  sizes  above  the  maximum 
packaging  capacity  were  not  efficiently  packaged  [31]. Packaging  of  viral  DNA  that  is  too  small 
results in destabilized virions, which would result in a growth disadvantage [44]. Since the minimal Ad 
cis-acting  sequences  and  the  transgene  are  usually  below  the  minimal  size  required  for  efficient 
packaging, the inclusion of a DNA stuffer is needed. The choice of DNA stuffer influences the vector 
stability, replication efficiency and in vivo performance [32,45]. A recent report by Smith et al. showed 
that HDAd virion with a genome size of ~30 kb were 100-fold more sensitive to heat inactivation than 
viruses with larger genome sizes (>36 kb) and that increasing the genome size significantly improved 
heat stability, but these smaller genome vectors were equally stable at physiologic temperatures [46]. It 
has been shown HDAd with bacteriophage lambda DNA as stuffer resulted in a decrease in the level 
and duration of transgene expression secondary to a cytotoxic T lymphocyte (CTL) immune response 
directed  against  the  peptides  derived  form  the  viral  backbone  [32].  Interestingly,  substituting  the 
lambda  stuffer  with  eukaryotic  DNA  sequences  such  as  human  hypoxanthine-guanine 
phosphoribosyltransferase gene, resulted in significantly higher transgene expression in the absence of 
CTL immune response, demonstrating the influence of the stuffer composition on the immunological 
properties of HDAd [32].  
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Figure 2. The Cre/loxP system for generating HDAds. The HDAd contains only ~500 bp 
of cis-acting Ad sequences required for DNA replication (ITRs) and packaging (ψ); the 
remainder of the genome consists of the desired transgene and non-Ad stuffer sequences. 
The HDAd genome is constructed as a bacterial plasmid (pHDAd) and is liberated by 
restriction enzyme digestion (e.g., PmeI). To rescue the HDAd, the liberated genome is 
transfected  into  293  cells  expressing  Cre  and  infected  with  a  helper  virus  bearing  a 
packaging signal (ψ) flanked by loxP sites. Cre-mediated excision of ψ renders the helper 
virus genome unpackageable, but still able to provide all of the necessary trans-acting 
factors  for  propagation  of  the  HDAd.  The  titer  of  the  HDAd  is  increased  by  serial 
coinfections of 293Cre cells with the HDAd and the helper virus. 
 
 
5. HDAd in vivo studies 
5.1. Liver directed gene therapy  
The liver is the key organ in many metabolic processes and is the affected organ in numerous 
inherited  metabolic  disorders.  Gene  therapy  strategies  aimed  at  targeting  the  liver  offer  several 
advantages: the fenestrated structure of its endothelium permits exposure of the parenchymal cells to 
systemically  delivered  vector,  transduced  hepatocytes  permit  the  secretion  of  the  vector  encoded 
transgene product, making the liver a factory for production and secretion of therapeutic proteins. To Viruses 2010, 2                         
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date, numerous examples of in vivo liver-directed gene therapy for disease models using HDAd have 
been reported. In general, all of these studies have demonstrated the tremendous therapeutic potential 
of HDAd vectors.  
Atherosclerosis is a common and complex pathological process
 characterized by intimal foam cell 
accumulation and extracellular
 matrix deposition in medium and large-sized arteries. A practical model 
for this disease is the apolipoprotein E knockout (apoE-/-) mouse [47,48]. To evaluate the efficacy of 
HDAd versus FGAd, hypercholesterolemic apoE-/- mice were injected with HDAd or FGAd encoding 
the mouse apoE cDNA (HD-Ad5-cE or FG-Ad5-cE) or a HDAd bearing the mouse genomic apoE 
locus (HD-Ad5-gE) [47]. Intravenous injection of apoE deficient mice with FG-Ad-cE or HD-Ad-cE 
resulted in a rapid increase of ApoE protein in the serum with a concomitant fall in plasma cholesterol 
levels to within normal range. However, in sharp contrast to FG-Ad-cE, in which the cholesterol level 
returned  to  the  pathological  levels  within  about  14  weeks,  normalization  of  cholesterolemia  by  
HD-Ad-cE  lasted  about  a  year  before  gradually  increasing.  Intravenous  injection  of  HD-Ad5-gE 
resulted in complete and immediate drop of plasma cholesterol to normal levels, staying within the 
normal range for the rest of the natural lifespan of the animal (about 2.5 years). Further analysis by 
quantitative morphometry of the aorta showed the absence of atherosclerotic plaques at two years after 
the HDAd injection. These results demonstrated the superiority of HDAd over FGAd and also that 
genomic based transgenes may be more effective than cDNA based transgenes.  
Simple  re-administration  of  the  vector  when  the  transgene  expression  fades  is  precluded  by 
neutralizing anti-Ad antibodies generated following the first administration. Indeed, mice previously 
injected with HD-Ad5-cE could not be successfully re-injected again. One potential solution is to use a 
different HDAd serotype for re-injection. In order to evaluate this strategy, Kim et al. generated a 
serotype  2  version  of  HD-Ad5-gE  (HD-Ad2-gE)  [47]  and  showed  that  it  could  be  successfully 
administered to mice previously treated with the serotype 5 (HD-Ad5-gE) to re-gain the expression of 
ApoE protein and lower plasma cholesterol levels. In this study, the authors also assessed the toxicity 
associated with the vectors and found that the FG-Ad5-cE vector resulted in significant hepatotoxicity 
as indicated by significant elevation of AST/ALT (>10- to 20-fold), whereas no such evidence of 
toxicity was associated with any of the HDAd vectors, even after a second administration with the 
serotype 2 HDAd [47]. In conclusion, this study demonstrated that: 1) a single intravenous injection of 
HDAd results in life-long expression of the therapeutic transgene and permanent phenotypic correction 
of  a  genetic  disease,  2)  the  large  cloning  capacity  of  the  HDAd  allows  for  the  delivery  of  the 
transgenes in their native genomic context, which resulted in superior kinetics and duration of the 
expression, 3) negligible toxicity was associated with HDAd administration, 4) administration of an 
alternative serotype HDAd is effective at circumventing the humoral immune response generated by 
the initial treatment.  
Crigler-Najjar syndrome type I is a severe inborn error of bilirubin metabolism due to mutations in 
the  uridinediphosphoglucuronate  glucuronosyltransferase  (UGT1A1)  gene.  Affected  patients  have 
increased serum bilirubin levels which may be life-threatening. Because of the risk of brain damage, 
patients  are  often  treated  with  liver  transplantation  [49].  Toietta  et al.  [50]  showed  that  a  single 
systemic injection of HDAd expressing UGT1A1 in Crigler-Najjar rats resulted in life-long expression 
of UGT1A1 and permanent phenotypic correction of the hyperbilirubinemia.  Viruses 2010, 2                         
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HDAd liver-mediated gene transfer can be considered an important tool for numerous diseases 
beyond  monogenic  disorders.  An  interesting  application  of  HDAd  for  the  treatment  of  diabetes 
mellitus has also been reported. In this study, two HDAds, one expressing Neurod1 (a transcription 
factor expressed in developing and adult β-cells of the pancreas) and another expressing betacellulin  
(a growth factor specific for β-cells), were co-injected into diabetic mice [51]. The results showed a 
normalization of glucose levels for the duration of the experiment (at least 120 days). This study 
showed that the manipulation of pancreatic precursor present in the liver, through the expression of 
critical  factors  for  their  development/differentiation  by  HDAd-liver  directed  gene  therapy,  can 
efficiently revert the diabetic phenotype in an animal model.  
An application of HDAd liver-directed gene therapy aimed at silencing a target gene by using short 
hairpin RNA (shRNA) has been recently reported. In this study, HDAd expressing shRNA directed 
against a transcription factor (SREBP1), which is upregulated in obese mice, showed a reduction in 
body weight [52]. In another application, the authors demonstrated the ability of HDAd-shRNA to 
silence the expression of specific mouse genes by approximately 75-90% [53]. It is remarkable that in 
contrast with previous studies showing severe toxicity and lethality following administration of AAV 
encoding shRNA, the HDAd expressing shRNA was well tolerated and showed only mild or low 
hepatotoxicity [53]. One of the major issues encountered with AAV shRNA vectors is the saturation of 
the  exportin-5  pathway,  which  shuttles  cellular  micro-RNA  (mi-RNA)  from  the  nucleus  to  the 
cytoplasm, and is thought to be involved in the observed toxicity with AAV [54]. In contrast, a similar 
mechanism was not seen with HDAd expressing shRNA [52]. These encouraging results with HDAd-
shRNA may pave the way to a variety of applications involving the silencing of dominant mutations 
causing genetic and acquired diseases.  
The impressive duration of transgene expression observed in rodents has been recapitulated in large 
animal models. In one study, two hemophilia B dogs injected 3 x 10
12 vp/Kg of HDAd expressing the 
canine factor IX resulted in a sustained phenotypic improvement of the bleeding diathesis for the 
duration of the experiment of at least 604 and 446 days [35]. Another group reported the correction of 
hemophilia  A  in  dogs  for  several  months  with  a  minimal  observed  liver  toxicity  [55].  Studies 
conducted in nonhuman primates convincingly demonstrated that HDAd was superior to FGAd with 
respect to duration of transgene expression and liver toxicity. In one of these studies, three baboons 
were  intravenously  injected  with  HDAd  expressing  hAAT  (human  α-1  anti-tripsin)  [56].  hAAT 
expression persisted for more than one year in two of the three animals. It was significant that no 
abnormalities in blood cell counts and liver enzymes were observed in these three baboons. In contrast, 
FGAd expressing hAAT generated a cellular immune response directed against the transduced cells 
causing loss of transgene expression. It was demonstrated that viral protein expressed from the FGAd 
viral backbone contributed to this loss [56]. These and other studies provide compelling evidence for 
using HDAd to treat genetic disorders. 
5.1.1. Nonlinear dose-response to hepatocyte transduction  
In the aforementioned studies, relatively high vector doses were used to achieve efficient hepatic 
transduction. Indeed, there is a non linear dose-response to the vector with high doses required for 
efficient hepatocyte transduction. This results in widespread vector dissemination as well as dose-Viruses 2010, 2                         
 
 
1894 
dependent activation of the innate immune response, resulting in acute toxicity with potentially severe 
and lethal consequences. This acute activation of the innate immune response is characterized by high 
levels of serum inflammatory cytokines and chemokines within a few hours post-injection. Kupffer 
cells (KC) in the liver play a major role in this non-linear dose-response by taking up the majority of 
the  viral  particles  that  reach  the  liver,  precluding  hepatocyte  transduction.  Furthermore,  systemic 
administration  of  Ad  vectors  likely  results  in  widespread  transduction  of  a  large  number  of 
extrahepatic tissues, which also contribute to inefficient hepatocytes transduction [57,58].  
Hepatocyte transduction in vivo doses not seem to be mediated by CAR receptor-and/or integrin but 
involve the interaction of Ad vector with bloodborne components such as coagulation factors and 
complement factors. Recent studies showed that pretreatment of mice with warfarin before Ad5 vector 
injection,  abrogates  liver  transduction.  Warfarin,  which  prevents  the  maturation  and  secretion  of 
functional  vitamin  K–dependent  coagulation  factors,  inactivates  several  proteins  belonging  to  the 
coagulation cascade pathway (factors II, VII, IX and X, anticoagulant protein C) and presumably 
inhibits the interaction between these factors and Ad5 vectors. It has been proposed that coagulation 
proteins act as a bridge between hepatocytes and Ad5 vector [59-63]. Recently, the mechanism by 
which factor X interact with Ad5 and promote the transduction of hepatocytes has been unraveled [64]. 
Electron cryomicroscopy studies determined that factor X binds within cavities formed by trimeric 
hexon  proteins  and  involves  interaction  with  the  Ad5  hexon  hypervariable  regions  [64].  This 
interaction  promotes  the  binding  of  the  Ad5–factor  X  complex t o   cellular  heparan  sulfate 
proteoglycans (HSPGs) and consequently, utilization of HSPGs as receptors by the Ad5–factor X 
complex,  and  not  CAR.  This  seems  to  be  important  for  liver  transduction  by  Ad5  after  systemic 
administration in vivo. Notably, in contrast with the species C serotypes Ad5 and Ad2, which have 
been shown to transduce hepatocyte after systemic injection, species B Ad35 and species D Ad26 have 
a weak if not absent binding to factor X and do not transduce the liver [65]. However, it is now clear 
that despite the fact that factor X facilitates Ad5 entry into hepatocytes, it is not required for trapping 
of vectors in the liver. Several other mechanisms contribute to the adenovirus sequestration by the liver 
[57], including: a) trapping of the virus by liver Kupffer cells and sinusoidal cells [66-68], b) Ad5 
penton RGD motif-mediated interactions with liver endothelial cells and hepatocytes with consequent 
retention  of  the  viral  particle  in  the  space  of  Disse  [57],  and  platelets  in  blood  may  contribute 
significantly to sequestration in the liver reticulo-endothelial system [69]. Di Paolo et al. [57] showed 
that  simultaneous  treatment  of  mice  with  clodronate  liposomes,  which  deplete  Kupffer  cells  and 
warfarin results in only a minimal reduction in sequestration in the liver. In addition, antibodies both 
specific and non specific for Ad, may also play a significant role in the non linear dose-response. 
Studies have shown that the threshold effect to hepatic transduction by Ad is reduced in antibody 
deficient Rag-1 and µMT mice [66,70]. One possible interpretation is that opsonization of the virion by 
antibodies may enhance the efficiency of Fc-receptor mediated uptake by Kupffer cells.  
5.1.2. Immunobiology of HDAd and pathogenesis of the acute toxicity 
Adenoviruses,  along  with  other  microorganisms,  following  infection,  are  subject  to  the  host 
immune response, which has evolved and adapted as a defense to fight off the pathogen invasion. 
Although early generation of Ad vectors are unable to replicate their genome, they still share several Viruses 2010, 2                         
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features  with  the  wt  Ad  counterpart.  Therefore,  systemic  delivery  of  these  vectors  in  animals  or 
humans  triggers  an  immune  reaction,  with  potentially  severe  consequences  for  the  host.  Systemic 
delivery of FGAd vectors is known to induce a potent cellular adaptive immune response against the 
viral  components  and  the  transgene,  and  a  non-specific  but  acute  innate  immune  response.  The 
immune reaction following FGAd administration in rodents or non human primates has been well 
characterized and comprises two phases. The first phase is mediated by the capsid and the second by 
expression of viral genes. After systemic injection of FGAd, the earliest phase occurs within minutes, 
is  characterized  by  acute  production  of  pro-inflammatory  cytokines  and  chemokines  such  as 
Interleukin-6/12,  RANTES  (regulated  upon  activation,  normal  T  cell  expressed  and
  secreted), 
macrophages  chemoattractant  protein-1  (MCP-1),  interferons  and  others,  and  its  severity  is  dose-
dependent  [34,71]  .The  high  level  of  serum  inflammatory  cytokines  and  chemokines  results  in 
systemic inflammatory response syndrome and multiple organ disfunction syndrome [4]. The second 
(e.g. chronic) phase lasts for days and occurs only with FGAd, and is associated with CTL mediated 
clearance of vector-transduced cells. It has been demonstrated that the first phase does not require 
transcription of viral genes but is initiated by the interaction of the viral capsid with the cells of the 
immune system [72]. Indeed, this acute toxicity is lethal in non human primates with both FGAd and 
HDAd  at  relatively  high  doses  [34,71].  The  innate  immune  response  following  intravascular 
administration of FGAd and HDAd vectors appears identical, and is complex and multifactorial.  
The important role of pattern recognition receptor (PRR), such as Toll-like receptors (TLR)-9 and 
TLR-2 in triggering the innate immune response has recently emerged [73]. TLR-2 is associated with 
the cellular membrane and is probably involved in the recognition of the capsid proteins [74,75]. 
However, the adenoviral ligand to TLR-2 has yet to be identified. TLR-9 is an endosomal receptor and 
recognizes  the  DNA  component  of  the  Ad  vectors  [76-78].  Ad  vector  interaction  with  these  two 
sensor-receptors  engages  a  complex  intracellular  pathways  through  the  activation  of  myeloid 
differentiation  primary  response  gene  88  (MyD88)  that  culminate  in  the  massive  production  of 
cytokine and chemokines, interferon (IF)-α and β and triggers dendritic cells (DCs) maturation and 
development of T-cell and B-cell responses against the Ad vector components [79]. The type I-IFs  
(α and β) activate natural killer (NK) cells and have a predominant role in the subsequent regulation of 
the  innate  immune  response  machinery  against  the  vector  [80].  Subsequent  activation  of 
chemoattractant  protein  (MIP-2),  Interleukin-1  and  tumor  necrosis  factor  contribute  to  leukocytes 
infiltration in the target tissue. NK cells activation releases several cytokines and promotes an adaptive 
immune response to the vector [81].  
Importantly, Ad vectors elicit the innate immune response either through MyD88/TLR or in an 
independent pathway depending on the cell type [73,82]. For example, DCs uses both MyD88 and 
TLR-9 for cytokine production, whereas activation of peritoneal macrophages and subsequent release 
of cytokines is independent of MyD88/TLRs system [73]. In the MyD88/TLR independent activation 
of  innate  immune  response,  double  stranded  viral  DNA  is  recognized  by  a  cytosolic  molecular 
complex  known  as  the  inflammasome.  The  inflammasome  consists  of  NALP3  and  ASC  adaptor 
protein complex, which induces maturation of pro-IL-1β in macrophages after the interaction with the 
viral DNA. This mechanism seems to be a key event in the innate immune response to Ad vectors and 
other DNA viruses. Another recent study by Di Paolo et al. identifies IL-1α-IL-1receptor-I (IL-1R-1) 
as  a  key  pathway  allowing  for  the  activation  of  pro-inflammatory  responses  to  the  virus  in Viruses 2010, 2                         
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macrophages, independently of recognition of the virus-associated nucleic acid by intracellular PRR 
[83]. The authors showed that the IL-1α-mediated response requires a selective interaction of virus 
RGD  motifs  with  macrophage  β3  integrins  in  response  to  Ad  vector,  leading  to  production  of 
inflammatory cytokines and chemokines [83].  
As already mentioned in the previous section, Ad vectors can also interact with various bloodborne 
components, which affects the efficiency of liver transduction and the tissue biodistribution. Moreover, 
blood  factors  including  complement  protein,  coagulation  system  and  both  neutralizing  and  non-
neutralizing antibodies may contribute to the acute toxicity. Ad has been shown to bind and activate 
the  complement  components  including  C3  and  C4BP  in  the  classical  and  alternative  complement 
pathways [84,85]. Complement and antibody interactions with Ad vectors result in an acute response 
with secretion of cytokines and chemokines [84]. These latter interactions promote the adhesion and 
migration  of  infiltrating  leukocytes  and  platelet  aggregation.  Thrombocytopenia  is  caused  by 
interaction between adenoviral particles and the coagulation system, resulting in formation of platelet-
leukocyte aggregates [81,86].  
It is worth mentioning that recombinant AAV (Adeno associated virus) vectors, like HDAds, are 
devoid of all viral gene sequences. In preclinical studies for liver-directed gene therapy, AAV vectors, 
similarly to HDAd, have shown to provide long-term transgene expression in mouse, dog and non 
human primates [87,87-91]. Despite these encouraging results, a human clinical trial for hemophilia B 
with AAV2 showed an unexpected outcome: subjects of the study developed transient elevation of 
liver enzymes and loss of FIX transgene expression after a few weeks secondary to a CTL immune 
response mediated by the re-activation of pre-existing AAV capsid-specific CD8+T memory cells [92]. 
This  CTL  response  occurred  in  the  absence  of  viral  gene  transcription  and  is  due  to  a  cross-
presentation of the AAV capsid input proteins through the major histocompatibility complex (MHC)-I 
[93]. Based on this experience with AAV, it will be important to determine whether a similar immune 
reaction will occur in humans following transduction by HDAd. Previous in vitro studies suggested 
that the induction of anti-Ad CTL is similar with either FGAd and HDAd [94] and that de novo 
expression of viral genes from Ad backbone is not a pre-requisite for elicitation of CTL immune 
response [95]. In addition, studies performed in naïve mice indicated that the key difference between 
FGAd and HDAd is that both initiate anti-Ad CTL against tranduced hepatocytes, but only FGAd-
transduced cells are cleared, probably due to the leaky expression of viral genes [3]. Finally, a recent 
study showed that pulmonary delivery of HDAd in mice results in eliciting CD8+ T cells that are able 
to trigger an adaptive immune response against the transduced cells even at low dose of vector [96,97]. 
However, comparative analysis between FGAd and HDAd are needed to address the role of the dose, 
species, and pre-immunization status of the host. Since the majority of the human have pre-existing 
immunity to Ad5, it may be necessary to develop strategies to prevent adaptive immune response 
against HDAd transduced cells before clinical translation. .  
5.1.3. Overcoming the threshold effect and the acute toxicity 
Strategies to overcome the hepatic threshold effects of transduction while reducing the systemic 
vector dissemination are highly desirable to improve the therapeutic index of HDAd for liver-directed 
gene therapy. Several approaches have been investigated and some are currently under investigation. Viruses 2010, 2                         
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Because the severity of the acute response is dose-dependent, some of these approaches are aimed at 
preferential targeting of the vector to hepatocyte thereby allowing for the use of lower vector doses. 
For example, injection of HDAd directly in the surgically isolated liver of nonhuman primates was 
shown to achieve higher efficiency hepatic transduction with reduced systemic vector dissemination, 
and stable, multi-year transgene expression without chronic toxicity [11]. However, the invasiveness of 
this method makes it clinically unattractive. Several studies suggested that the liver microarchitecture 
plays a prominent role in the liver transduction efficiency by Ad vectors. The size of the sinusoidal 
endothelial  fenestrae  (SEF)  of  the  liver,  which  is  approximately  100  nm,  plays  a  critical  role  in 
hepatocyte transduction by Ad since the Ad virion size is ≥100 nm. It has been shown that there is a 
direct correlation between the size of the SEF and the efficiency of hepatocyte transduction following 
systemic  administration  of  Ad  [98,99].  Therefore,  physical  or  chemical  methods  to  enlarge  SEF 
diameter could have a positive impact on the therapeutic index of Ad vectors, by increasing hepatocyte 
transduction with lower vector doses thereby reducing the acute toxicity. The size of the SEF can be 
enlarged by means of drugs such as Na-decanoate or N-acetylcysteine [98], combined with transient 
liver ischemia or pretreatment with the neuropeptide vasoactive intestinal peptide (VIP) [100] among 
others.  Another  interesting  approach  to  enlarge  the  SEF  in  rodents  is  increasing  the  intrahepatic 
pressure by hydrodynamic injection (h.i.), a technique which involves the rapid tail vein injection of 
large volumes [101-103]. In mice, h.i. of HDAd results in improved hepatocyte transduction with 
concomitant reduction of the systemic dissemination of the vector [102]. However, further studies are 
necessary to determine the real clinical potential of these SEF enlarging drugs, and h.i. as performed in 
rodents is not suitable for human application due to the requirement of rapid, large volume injection. 
Interestingly, h.i. studies suggested that high efficiency of hepatic transduction does not, at least alone, 
necessarily provoke a potent inflammatory response and that systemic dissemination of the vector may 
play a major role in the severity of the inflammatory response [102]. A clinically attractive method of 
delivering HDAd which mimics h.i. has been developed for large animals by using balloon occlusion 
catheters [37]. In this approach, referred as pseudo-hydrodynamic injection, hepatic venous outflow is 
occluded using two balloon occlusion catheters percutaneously placed in the inferior vena cava (IVC), 
above and below the hepatic veins (HV). An increase in intrahepatic pressure with this method is 
achieved because blood that enters the liver from the hepatic artery (HA) and portal vein (PV) remains 
unobstructed, thus mimics the high pressures achieved by systemic hydrodynamic injections in mice. 
this approach resulted in high efficient liver transduction with minimal toxicity and long-term gene 
expression  [37].  More  recently,  an  improved  minimally  invasive  balloon  occlusion  method  was 
reported to achieve high efficiency hepatocyte transduction using clinically relevant low HDAd doses 
(Figure 3). In this method, a single sausage shaped balloon was inflated in the inferior vena cava (IVC) 
to occlude the hepatic venous outflow and the HDAd was injected directly into the liver via the hepatic 
artery  resulting  in  up  to  80-fold  higher  levels  of  transgene  expression  compared  to  the  systemic 
administration which persisted for more than 2.5 years [38]. Acute toxicity associated with this method 
of HDAd delivery was mild to moderate and transient. 
Alternative strategies to attenuate the innate immune response are currently under investigation. 
One potential approach to reduce the visibility of the Ad vector to the immune system is the alteration 
of the capsid surface by virion encapsidation with cationic liposome [104] which resulted in 70-80% 
decrease in serum cytokines compared to unencapsidated virions without compromising the hepatic Viruses 2010, 2                         
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transduction  efficiency.  Another  approach  consists  in  the  administration  of  PEGylated  Ad  vectors 
which resulted in a 50% to 70% decrease in serum cytokine compared to un-PEGylated Ad [105-107]. 
In a recent study the combination of methylprednisolone, an anti-inflammatory glucocorticoid, and 
PEGylated  Ad  potently  inhibited  IL-6  elevation  [108].  Finally,  it  has  been  reported  that  a  single 
administration of dexamethasone, another anti-inflammatory glucocorticoid, prior to Ad administration 
was able to significantly reduce both innate and adaptive immune response [109]. 
Figure 3. (A) A sausage-shaped balloon catheter is positioned in the inferior vena cava 
(IVC)  under  fluoroscopic  guidance.  Inflation  of  the  balloon  results  in  hepatic  venous 
outflow occlusion from the hepatic veins (HV). The HDAd is administered by injection 
through a percutaneously positioned hepatic artery (HA) catheter. (B). Serum levels of the 
reporter  baboon  α-fetoprotein  (bAFP)  following  administration  of  3x10e10  vp/kg  of  a 
HDAd expressing bAFP into baboons using the balloon method described above (squares) 
or  by  simple  peripheral  intravenous  injection  (circles).  The  balloon  method  of  vector 
delivery yielded up to 80-fold higher level of transgene expression compared to peripheral 
intravenous injection of vector, and transgene expression persisted at high levels for at least 
2.5 years. 
 
 
5.2. Gene therapy of Cystic Fibrosis lung disease 
Cystic  fibrosis  (CF)  is  the  most  common  life-limiting  autosomal  recessive  disease,  and  it  is 
estimated that 1 in 2500 Caucasian newborns are affected with CF
 although higher frequencies have 
been found in inbred population groups such as the Hutterites in Alberta, Canada (incidence of 1 in 
313), Afrikaners in South Africa (1 in 355)
 and French Canadians (1 in 895) [110]. CF is a life-
threatening disease and is characterized by chronic lung infections and inflammation that results in a Viruses 2010, 2                         
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life expectancy of 30-35 years [111]. The CF gene, termed CFTR (cystic fibrosis transmembrane 
conductance regulator), is a chloride channel expressed on the apical side of the airway epithelial cells. 
The lack of CFTR in CF patients causes a defect in water and ions exchange through the airway 
epithelium resulting in formation of thick mucus and subsequent lung inflammation and infection.  
Gene therapy strategies are highly desirable and attractive for CF because it is a monogenic disease 
with the main pathology in the lung, which is relatively easy to access for treatment. Theoretically, one 
single administration of a gene delivery vector expressing CFTR could be effective in restoring the 
protein activity and cure the disease.  
Several  methods  and  strategies  have  been  investigated  and  Ads  are  amongst  the  most  utilized 
vectors. In fact, FGAds have been extensively pursued for the treatment of CF in animal models as 
well as in humans. Unfortunately, they have shown to be inadequate, having numerous disadvantages 
and serious shortcomings. The first obstacle encountered was the absence of the CAR receptors on the 
apical surface of the airway epithelial cells, which constitutes a barrier to adenovirus-mediated gene 
delivery
 in vivo.  It  was  discovered  that  the  CAR  resides  on  the  basolateral  surface  of  the  airway 
epithelial  cells  and  that  the  tight  junctions  prevent  the  interaction  between  Ad  and  its  receptor, 
precluding efficient transduction [112,113]. Another drawback that is associated with the use of FGAd 
is  the  adaptive  immune  response  elicited  by  the  residual  viral  gene  expression  from  the  vector 
backbone. Indeed, pulmonary delivery of FGAd in non human primates and human results in a dose-
dependent inflammation and pneumonia [114-117]. In order to overcome the barrier represented by the 
absence of apical receptors, several strategies have been pursued based on the transient disruption of 
tight junctions. It has been shown that pre-treatment with EGTA, EDTA, polycations and other agents 
[118-120]  is  able  to  relax  the  tight  junction  and  improve  the  delivery  of  Ad  vectors  into  airway 
epithelia. To overcome the cytotoxicity and the adaptive immune response against FGAds, multiple 
deleted Ads have also been used. These vectors were able to reduce but not eliminate the inflammation 
and pneumonia which is likely due to a leaky expression of the viral late genes [121,122]. In contrast 
to FGAds, HDAds have shown to be very promising for the treatment of CF. Toietta et al. showed that 
HDAd delivered to the airway of mice resulted in an absence of pulmonary inflammation and the 
duration of transgene expression persisted at least for 15 weeks [5]. The studies with HDAd vectors 
have also shown that the human cytokeratin 18 promoter (K18) is expressed, similarly to the mouse 
CFTR, in the epithelium of the large airways and bronchioles and in sub-mucosal glands with a little 
expression in alveoli. Specifically, one study with HDAd encoding CFTR under K18 control delivered 
to CFTR-/- mice lung, showed the correct localization of the CFTR protein in the appropriate target 
cell  types  and  the  protection  of  the  lungs  from  opportunistic  infections  [123].  This  latter  feature 
suggests that HDAd has the potential to reduce the susceptibility to opportunistic pathogens in CF 
patients. However, to successfully deliver the vector to the correct cell types in the above experiments, 
Koehler  et  al.  pretreated  CFTR-/-  mice  with  EGTA  to  open  the  tight  junctions.  Despite  the 
encouraging results obtained in these experiments, the requirement for two separate administrations, 
one for EGTA and one, 30 minutes later, for the HDAd vector, is suboptimal in terms of safety and 
efficacy. Indeed, to fully take advantage of EGTA pre-treatment, both the vector and EGTA need to be 
delivered in the same location, which is not guarantee in the case of two independent administrations. 
This issue was addressed by Koehler et al. [124] in another study in which they demonstrated the 
superior  efficacy  of  HDAd  vector  formulated  with  0.1%  L-α-lysophosphatidylcoline  (LPC).  This Viruses 2010, 2                         
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specific formulation of the vector permitted one single efficient administration of HDAd along with 
the tight junction opening agent. However the intranasal delivery of the vector as performed in mice 
(spontaneous liquid inhalation) is not clinical relevant for larger animal and humans. To overcome this 
obstacle, Koehler et al. [124] used an intracorporeal nebulizing catheter (Aeroprobe) to aerosolize the 
HDAd-LPC  solution  directly  into  the  trachea  and  lungs  of  rabbits.  They  showed  that  the  HDAd 
administered in this way was able to achieve high level of transgene expression in the proximal and 
distal  airway  epithelium,  from  the  trachea  to  terminal  bronchioles  (Figure  4).  This  strategy  of 
delivering HDAd to rabbits has recently been applied to non human primates with similar encouraging 
results [125]. 
Disruption of tight junctions is clearly effective for increasing transduction of the airway and this 
treatment is well tolerated in animal models. Indeed, repeated aerosolization of EDTA into CF patients 
resulted in no harmful effects [126]. However, it would be highly desirable if this intervention could be 
avoided. Thus, development of modified HDAd able to transduce the airway epithelium via the apical 
surface  would  be  very  attractive.  It  should  be  pointed  out  that  the  aforementioned  studies  were 
performed in animal models with healthy airways and that transduction will likely be reduced in the 
lungs affected by multiple bacterial colonizations and thick mucus such as the human CF lungs. Up to 
now, efficacy of gene therapy has been only addressed in animal models with unaffected airways such 
as the CFTR knock-out mice and the nonhuman primates. The recently developed pig model for CF 
could potentially provide a better model for assessing the efficacy of experimental treatments in the CF 
lung  disease  [127].  However,  several  strategies  can  be  envisioned  to  address  this  obstacle  in  the 
clinical  setting.  For  example,  severely  affected  CF  patients  may  undergo  commonly  employed 
regimens to clear their lungs before gene transfer. This could include inhaled antibiotics (such as 
Tobramycin) and systemic intravenous anti-pseudomonal antibiotics (such as aminoglycosides, beta 
lactams, fluoroquionoes), pulmonary treatment with mucolytic agents (such as Pulmozyme), along 
with mechanical airway clearance to reduce the amount of mucus. Conducting gene transfer in CF 
patients with less affected lungs may be an alternative option, including the enrollment of younger CF 
patients with little or no lung disease. While somewhat controversial, this is not without precedence. 
Indeed, in a recent clinical trial using AAV, CF patients as young as 12 years of age were enrolled 
[128]. .In summary, while the thickened mucus remains a barrier for all gene transfer vectors (viral or 
nonviral)  as  well  as  for  small  molecule  therapeutics  we  do  not  believe  it  to  be  insurmountable, 
especially considering the low levels of gene transfer that may be required which has been estimated to 
be 5 to 10% [129]. 
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Figure 4. Pulmonary transduction in rabbits following intratracheal aerosolization of L-a 
lysophosphatidylcholine  and  HDAd  expressing  LacZ  under  the  control  of  the  K18 
promoter. X-gal stained (A) trachea, (B) right upper lobe, (C) left lower lobe, (D) right 
lower lobe and (E) bronchus and bronchioles. 
 
 
5.3. HDAd for muscle-directed gene therapy 
Duchenne Muscular Dystrophy (DMD) is an X-linked lethal disorder that affects 1 in 3500 male 
births and is caused by genetic mutation in the dystrophin gene. The protein dystrophin is an essential Viruses 2010, 2                         
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structural component of the skeletal muscle cell membrane and its deficiency results in instability of 
the muscle cell and fiber degeneration. Since there is a lack of effective treatments, gene therapy 
strategies aimed at transferring normal copies of the dystrophin gene into the muscle fibers of patients, 
appears one of the most desirable options to cure this disease. The cDNA for full-length dystrophin is 
approximately 14 kb, far above the size of most of gene therapy vectors [130]. HDAd has opened the 
possibility to treat DMD animal models due to its large cloning capacity (up to 37 kb) which can 
accommodate  up  to  two  copies  of  the  dystrophin  gene  [131,132].  HDAds  expressing  full-length 
dystrophin gene have been shown to restore the full dystrophin-glycoprotein complex in the skeletal 
muscle. In these studies, neonate skeletal muscles of mdx mice (a model for DMD) injected with 
HDAd were able to express dystrophin for the duration of the experiment (up to one year) resulting in 
the amelioration of the pathogenesis of the disease and in a reduced level of muscle degeneration with 
functional correction of muscle contractility [131]. However a significant inflammatory response was 
been observed which was accompanied by humoral response against the murine dystrophin protein 
expressed by transduced muscle. This immune response may also occur in humans, as many DMD 
patients have a large dystrophin gene deletion. Therefore the dystrophin encoded by gene transfer 
vectors may be seen as a foreign antigen with the consequent development of an adaptive immune 
response and loss of long-term phenotypic correction. One potential strategy to bypass the immunity 
against the protein is the co-delivery of immunomodulatory molecules able to blunt the innate and 
adaptive immune response. Jiang et al. demonstrated that blockade of the costimulatory interaction 
between naïve T cells and antigen-presenting cells by co-delivering CTLA4Ig alone or in combination 
with CD40Ig, diminishes innate and adaptive immunity induced by HDAd-dystrophin and prolong the 
transgene expression [4,133,134]. HDAd have also been explored for in utero gene therapy for DMD. 
The immaturity of the fetal immune system accompanied by the survival advantage of the muscle cells 
expressing dystrophin over the dystrophin-deficient fiber, makes this approach very attractive. The 
application of this strategy in vivo, showed that HDAd is less toxic compared to FGAd and capable of 
driving stable transgene expression and restoration of the sarcoglycan complex [135]. In order to be an 
effective treatment for this disease, dystrophin needs to be expressed by multiple muscles, including 
the  diaphragm  because  respiratory  dysfunction  is  a  main  cause  of  death  among  DMD  patients  
[136-138]. Therefore, diaphragm-directed gene therapy has been investigated in mdx mice with HDAd 
which leads to reversal of functional abnormalities of dystrophic diaphragms for at least 30 days [138].  
The muscle is a very attractive target for gene transfer because, like the liver, it can be used as a cell 
factory for production and secretion of therapeutic proteins. In fact, skeletal myofibers constitute about 
40% of the total body mass, have a relatively long half-life and can be easily transduced in vivo 
because of easy access. High seroprevalence of pre-existing anti-Ad neutralizing antibody in the adult 
human population represents an obstacle for intravenous delivery, and it has been shown that this 
could  be  minimized  by  local  delivery  of  the  vector.  Interestingly,  when  HDAd  was  injected 
intramuscularly (i.m) into previously immunized mice, stable transgene expression could be achieved; 
in contrast, the same mice injected i.m. with FGAd lost transgene expression after three week [139]. 
This study also showed that even though it is possible to administer HDAd into pre-immunized mice, a 
30-  to  100  fold  higher  dose  (compared  to  naïve  mice)  was  required  to  achieve  87%  and  100% 
transduction of the muscles. 
Finally, another hurdle that hampers muscle-directed gene therapy with Ad vectors is that mature Viruses 2010, 2                         
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muscle is not transduced efficiently because of low level of CAR receptor expression on the surface of 
adult muscle cells. Bramson L. et al, showed that the incorporation of polylysine into the H-I loop of 
the adenoviral fiber protein can improve HDAd transduction of mature muscle cells, giving up to  
21- fold increase compared to the unmodified counterpart [140]. 
5.4. Gene therapy for brain and eye 
Because of their intrinsic ability to infect post-mitotic cells and to mediate long-term transgene 
expression, Ad vectors constitute a very promising gene-delivery platform for central nervous system 
(CNS) disorders [141]. The above features are critical in order to successfully treat disorders ranging 
from simple monogenic disorders (such as Lesh-Nyhan syndrome, leukodistrophies, lysosomal storage 
diseases, amyotrophic lateral sclerosis among others) to multifactorial diseases including Parkinson’s 
disease and Alzeimer’s disease.  
Following systemic administration of an FGAd vector, a rapid decline in transgene expression has 
been observed in peripheral organs whereas the same FGAd vector is able to stably transduce adult 
brain  cells  [142-144].  Indeed,  intraparenchymal  injection  of  FGAd  vectors  into  the  brain  elicits  a 
minimal,  transient  local  inflammation  which  does  not  compromise  the  duration  of  transgene 
expression. One possible explanation for this phenomenon is the “immune-privileged” status of the 
brain, being relatively protected from the effect of the immune response. In fact, Ad injections into the 
brain result in an ineffective T cell response against brain-transduced cells in presence of viral protein 
expression from the backbone of FGAd vectors [145,146]. However, the immune system can respond 
to antigenic stimuli in the brain if the host organism has pre-existing immunity against that antigen, 
which would be the case for pre-immunization or re-administration with the same vector. In this case, 
loss of transgene expression and chronic inflammation are observed following FGAd injection into the 
brain [147]. In contrast, injection of HDAd into the brain of pre-immunized mice does not show these 
detrimental  effects.  Instead,  HDAd  was  able  to  mediate  significantly  higher  levels  of  transgene 
expression with substantially reduced immune response [147,148]. Recently, interesting results have 
been reported by delivering HDAd into the cerebrospinal fluid through a lumbar puncture in primates 
[149]. In this study, it was shown that injection of an HDAd vector by lumbar puncture into the 
cerebrospinal fluid (CSF) of non-human primates allows long-term (three months) transduction of 
neuroepithelial cells. This result was also observed in monkeys bearing a pre-existing anti-adenoviral 
immunity  [149].  Another  study  from  the  same  authors  showed  that  by  using  the  same  route  of 
administration  in  immune-competent  mice,  it  was  possible  to  deliver  HDAd  expressing  anti-
inflammatory  cytokines  and  achieve  long  term  transgene  expression  without  any  signs  of  toxicity 
[150]. This latter strategy makes HDAd-CSF gene delivery a very attractive therapeutic approach for 
brain inflammatory condition such as multiple sclerosis.  
Encouraging  results  have  been  obtained  in  a  study  in  which  stereotactic  injection  of  HDAd 
expressing a short hairpin RNA to silence the Huntington disease gene was able to inhibit Huntington 
protein  aggregation  [151,152].  However,  the  vector  had  limited  brain  distribution  not  extending 
beyond a few millimeters from the needle track, making this approach still far from optimal. The brain 
is a complex organ with intricate interconnections between various cell types and therefore it could be 
challenging to develop a targeting strategy with HDAd for the correction of diseases with diffuse Viruses 2010, 2                         
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involvement. Nevertheless, diseases requiring localized gene delivery to a discrete set of neurons such 
as Parkinson’s disease or brain tumors may be more suitable. 
HDAd  vectors  have  recently  emerged  as  an  important  therapeutic  strategy  for  brain  tumor 
treatment. In a preclinical study for the treatment of glioblastoma multiforme, intratumoral injection 
with HDAd encoding the conditionally cytotoxic herpes simplex type 1 thymidine kinase (TK) and the 
immunostimulatory cytokine fms-like tyrosine kinase ligand 3 (Flt3L) was associated with increased 
survival and development of antiglioma immunological memory without signs of neuropathology or 
systemic toxicity [153]. Given the high risk that FGAd treatment of glioblastoma multiforme can be 
compromised by prior exposure to natural Ad infection, HDAd vectors could offer a safer and more 
effective treatment for patients with this type as well other types of brain cancer.  
There have been a limited number of studies investigating HDAd vectors for ocular gene therapy. In 
one study, HDAd vector was able to transduce and rescue cells from the neurosensory retina in a 
mouse model of retinal degeneration [154]. Moreover, HDAd vectors showed a great potential in 
targeting the retinal pigment epithelium following subretinal injection, without evidence of adverse 
immune reactions [155]. 
5.5. Ex vivo gene therapy in human patients 
HDAd has recently been used in a clinical trial to treat anemic chronic kidney disease (CDK) 
patients [159]. In this Phase I-II study, a small number of autologous dermal fibroblasts were removed 
from under the skin of anemic CDK patients under local anesthesia and transduced ex vivo with an 
HDAd expressing erythropoietin (EPO). Following transduction, the amount of EPO produced by the 
transduced cells was measured so that the precise number of transduced cells could be reimplanted 
subcutaneously to achieve the requisite dose of EPO. No adverse events were reported in this trial and, 
importantly, elevated hemoglobin levels were sustained for up to one year after a single treatment with 
the  HDAd  transduced  cells.  Significantly,  this  study  also  clearly  demonstrates  that  HDAd  can  be 
manufactured under cGMP. 
5.6. HDAd as genetic vaccines 
FGAds have been developed to express antigens and have proven to be valuable genetic vaccines. 
Recent studies have shown that HDAd may be superior than FGAd for this application. For example, 
Harui et al. [156] compared the ability of FGAd and HDAd expressing β-galactosidase to generate an 
immune response in mice and found that HDAd generated a stronger T cell and antibody response 
against  β-galactosidase  than  FGAd.  Weaver  et  al.  [157]  also  found  that  HDAd-based  vaccines 
generated stronger immune responses against the encoded antigen than FGAd-vaccines in mice. In 
addition, administration of HDAd–based vaccines resulted in lower tissue damage and anti-Ad T cell 
responses than FGAd. Weaver et al. [157] also demonstrated that HDAd induced anti-HIV immune 
response in rhesus macaques. In a subsequent study, Weaver et al. [158], demonstrated that rhesus 
macaques vaccinated with HDAd expressing HIV-1 envelope protected the animals from subsequent 
mucosal SHIV challenge. Because most humans are seropositive for adenovirus serotype 5, HDAd 
vaccines based on serotype 5 may be minimally, if at all, effective. To overcome this, Weaver et al. 
used HDAd vaccines based on serotypes 1, 2 and 6 and showed that the presence of pre-existing Viruses 2010, 2                         
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immunity to adenovirus serotype 5 in both the mice and rhesus macaques did not prevent successful 
vaccination [157,158]. These studies demonstrate the potential utility of HDAd as a genetic vaccine. 
6. Concluding remarks and future perspectives 
HDAd possess many characteristics that make them attractive vectors for gene transfer of a wide 
variety of applications. However, a major concern regarding clinical application of HDAd is the host 
innate inflammatory response against the vector capsid that occurs shortly after administration. This 
concern is primarily problematic for intravascular delivery as it does not appear as severe for other 
routes of administration. This innate immune response is multifactorial and its mechanism(s) remains 
largely unknown although some of the components involved are being progressively identified. Given 
the complexity of this reaction, it will be challenging to design strategies to minimize or reduce the 
severity of this response. Moreover, the fundamental differences among species make it difficult to 
predict the outcome in humans based on the result of the preclinical animal testing. Regardless of the 
multiple mechanisms involved, strategies to improve the transduction efficiency using lower vector 
doses are clinically attractive because the innate response is dose-dependent. Another problem is that 
most humans have pre-existing immunity to serotype 5 adenovirus. Since most current HDAd are 
based on serotype 5, concerns regarding reduced efficacy and increased toxicity in the face of pre-
existing immunity must be considered. Possible solutions to this problem include PEGlyation of the 
vector or using HDAds derived from different, less common serotypes or even HDAd derived from 
non-human adenoviruses. We are optimistic that these barriers will be surmountable as research into 
their solutions is ongoing.  
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